Oncology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company also plans to submit an MAA to the EMA in the first half of 2024.

The FDA has received reports of multiple T-cell malignancies in patients after approved CAR-T treatment.

Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.

Review top news and interview highlights from the week ending November 24, 2023, including coverage from AHA 2023.

The new PDUFA date of lifileucel is set for Februrary 24, 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The date for the AdComm and the new PDUFA date are yet to be announced.

The PDUFA date for Iovance’s lead TIL lifileucel for melanoma was recently pushed back to February 24, 2024.

Review top news and interview highlights from the week ending November 17, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The median progression-free survival was 11 months and the SCG101 was well-tolerated.

Review top news and interview highlights from the week ending November 10, 2023.

Ben Creelan, MD, a medical oncologist at Moffitt Cancer Center, discussed several different approaches to cell therapy that could lead to new treatment options in the field.

Microsatellite instability (MSI) tumors are frequently found in people with Lynch syndrome, one of the most common hereditary colorectal cancers.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

BRL Medicine is also enrolling a phase 1/2 multicenter trial evaluating BRL-201 at lower dose ranges.

The BASECAMP-1 screening study has now identified 28 patients whose solid tumors are positive for HLA-A*02 LOH.

David Rawlings, MD, the director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute, discussed findings from several preclinical studies that could help push engineered B-cell therapies towards clinical trials.

Patients with HNSCC had a median overall survival (OS) of 20.8 months and a 12-month OS rate of 59%.

In terms of safety, it was noted that repeated administration of CAR mRNA/LNP was well-tolerated by mice.

Review top news and interview highlights from the week ending Novmber 3, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CARVac RNA vaccine may amplify the persistence of the BNT211 CAR T-cell therapy.

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious.

In light of the IND clearance, the company is planning to carry out plans for a phase 1 clinical trial (AMpLify) for adult patients with r/r AML.

The combo, termed MB-109, consists of the MB-108 oncolytic virus and MB-101 CAR T-cell therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

October is National Breast Cancer Awareness Month, and thus serves as an additional moment to point to the progress made in cell and gene therapy development, as well as the lingering challenges.

The first patient will be treated with CTO1681 at UPMC Hillman Cancer Center.